Prevention of pneumococcal disease in adults in primary health care: future perspectives
DOI:
https://doi.org/10.32385/rpmgf.v39i6.13548Keywords:
Pneumococcal disease, Pneumococcal vaccines, Invasive pneumococcal disease, Pneumococcal infections, Streptococcus pneumoniae, PneumoniaAbstract
Pneumococcal disease is a public health priority in the adult population. Streptococcus pneumoniae causes pneumococcal disease and older people and those with chronic diseases or immunocompromised are at increased risk. Pneumococcal vaccines reduce the incidence of pneumococcal disease, particularly invasive disease. However, some serotypes not included in current vaccines have emerged as an important cause of invasive pneumococcal disease (IPD). Greater vaccination coverage of the adult population could reduce the burden of pneumococcal disease. There are national and international recommendations for pneumococcal immunization. As a result of the development of the PCV15 and PCV20 conjugate vaccines, the recommendations should be revised according to recent scientific evidence. Given the Portuguese epidemiological reality of IPD, the preferential implementation of a simple and universal national vaccination strategy based on a single dose of the PCV20 conjugate vaccine may contribute to faster and longer-lasting health gains. The family doctor plays a key role in the prevention and implementation of pneumococcal vaccination in the adult population, aiming for their protection and better health outcomes.
Downloads
References
World Health Organization. Vaccines and immunization [homepage]. Geneva: WHO; [s.d.] [cited 2022 Jun 12]. Available from: https://www.who.int/health-topics/vaccines-and-immunization#tab=tab_1
Rodrigues CM, Plotkin SA. Impact of vaccines: health, economic and social perspectives. Front Microbiol. 2020;11:1526.
Costa RP, Gonçalves C, Sousa JC. A doença pneumocócica e recomendações GRESP para a vacinação antipneumocócica na população adulta (≥18 anos) [GRESP recommendations for anti-pneumococcal vaccination in adults]. Rev Port Med Geral Fam. 2016;32(1):70-4. Portuguese
Horácio AN, Diamantino-Miranda J, Aguiar SI, Ramirez M, Melo-Cristino J, Portuguese Group for Study of Streptococcal Infections. Serotype changes in adult invasive pneumococcal infections in Portugal did not reduce the high fraction of potentially vaccine preventable infections. Vaccine. 2012;30(2):218-24.
Silva-Costa C, Gomes-Silva J, Prados L, Ramirez M, Melo-Cristino J, Portuguese Group for the Study of Streptococcal Infections, et al. Pediatric invasive pneumococcal disease three years after PCV13 introduction in the National Immunization Plan-the continued importance of serotype 3. Microorganisms. 2021;9(7):1428.
Silva-Costa C, Gomes-Silva J, Teodoro I, Ramirez M, Melo-Cristino J, The Portuguese Group for the Study of Streptococcal Infections. Invasive pneumococcal disease in adults in Portugal: the importance of serotypes 8 and 3 (2015-2018). Microorganisms. 2021;9(5):1016.
Chandler T, Furmanek S, Carrico R, Balcom D, Arnold F, Ramirez J. 23-Valent pneumococcal polysaccharide vaccination does not prevent community-acquired pneumonia hospitalizations due to vaccine-type streptococcus pneumoniae. Microorganisms. 2022;10(3):560.
Marra F, Zhang A, Gillman E, Bessai K, Parhar K, Vadlamudi NK. The protective effect of pneumococcal vaccination on cardiovascular disease in adults: a systematic review and meta-analysis. Int J Infect Dis. 2020;99:204-13.
Direção-Geral da Saúde. Vacinação contra infeções por Streptococcus pneumoniae de grupos com risco acrescido para doença invasiva pneumocócica (DIP) – adultos (≥18 anos de idade): norma nº 011/2015, de 23/06/2015, atualizada em 01/11/2021. Lisboa: DGS; 2021.
Ermlich SJ, Andrews CP, Folkerth S, Rupp R, Greenberg D, McFetridge RD, et al. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naïve adults ≥50 years of age. Vaccine. 2018;36(45):6875-82.
Peterson JT, Stacey HL, MacNair JE, Li J, Hartzel JS, Sterling TM, et al. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults ≥65 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Hum Vaccin Immunother. 2019;15(3):540-8.
Platt HL, Cardona JF, Haranaka M, Schwartz HI, Narejos Perez S, Dowell A, et al. A phase 3 trial of safety, tolerability, and immunogenicity of V114, 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal conjugate vaccine in adults 50 years of age and older (PNEU-AGE). Vaccine. 2022;40(1):162-72.
Mohapi L, Pinedo Y, Osiyemi O, Supparatpinyo K, Ratanasuwan W, Molina JM, et al. Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in adults living with HIV: a randomized phase 3 study. AIDS. 2022;36(3):373-82.
Song JY, Chang CJ, Andrews C, Diez-Domingo J, Oh MD, Dagan R, et al. Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by sequential PPSV23 vaccination in healthy adults aged ≥50 years: a randomized phase III trial (PNEU-PATH). Vaccine. 2021;39(43):6422-36.
Essink B, Sabharwal C, Xu X, Sundaraiyer V, Peng Y, Moyer L, et al. 3. Phase 3 pivotal evaluation of 20-valent pneumococcal conjugate vaccine (PCV20) safety, tolerability, and immunologic noninferiority in participants 18 years and older. Open Forum Infect Dis. 2020;7(Suppl 1):S2.
Klein NP, Peyrani P, Yacisin K, Caldwell N, Xu X, Scully IL, et al. A phase 3, randomized, double-blind study to evaluate the immunogenicity and safety of 3 lots of 20-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naive adults 18 through 49 years of age. Vaccine. 2021;39(38):5428-35.
Hurley D, Griffin C, Young M, Scott DA, Pride MW, Scully IL, et al. Safety, tolerability, and immunogenicity of a 20-valent pneumococcal conjugate vaccine (PCV20) in adults 60 to 64 years of age. Clin Infect Dis. 2021;73(7):e1489-97.
Matanock A, Lee G, Gierke R, Kobayashi M, Leidner A, Pilishvili T. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: updated recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep. 2019;68(46):1069-75.
Portaria nº 200/2021, de 21 de setembro. Diário da República. I Série;(184).
Kobayashi M, Farrar JL, Gierke R, Britton A, Childs L, Leidner AJ, et al. Use of 15-valent pneumococcal conjugate vaccine and 20-valent pneumococcal conjugate vaccine among U.S. adults: updated recommendations of the Advisory Committee on Immunization Practices – United States, 2022. MMWR Morb Mortal Wkly Rep. 2022;71(4):109-17.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Portuguese Journal of Family Medicine and General Practice
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The authors will assign to the RPMGF the sole right to publish and distribute the content of the manuscript specified in this declaration via physical, electronic, broadcasting or any other medium that may come into existence. They also grant the RPMGF the right to use and exploit this manuscript, in particular by assigning, selling or licensing its content. This permission is permanent and takes effect from the moment the manuscript is submitted, has the maximum duration allowed by applicable Portuguese or international law and is of worldwide scope. The authors further declare that this assignment is made free of charge. If the RPMGF informs the authors that it is not going to publish their manuscript, the exclusive assignment of rights ceases forthwith.
The authors authorise the RPMGF (or any entity it may appoint) to act on their behalf when it believes that copyright may have been infringed.
